Managed Healthcare Executive November 22, 2021
Jeff Baldetti

Momentum is building for biosimialrs but robust coverage for lower-cost agents, including biosimilars, is needed.

Six years after the first biosimilar was approved by the FDA, the U.S. is on the verge of finally realizing the broad benefits these products can bring to patients across a range of therapeutic areas.

2021 has been particularly strong for the growth of biosimilars in oncology, led by biosimilars referencing major therapeutic oncology products Avastin, Herceptin, and Rituxan. With added government support through bills such as the Advancing Education on Biosimilars Act of 2021, and new proposed legislation including the HHS response letter to the July 9th Executive Orders, biosimilars remain a primary focus from a policy perspective.

In addition to new policies, the U.S. saw...

Today's Sponsors

Qure4u
HLTH
ZeOmega

Today's Sponsors

Premier
TripleTree

Today's Sponsor

Transcarent

 
Topics: Biotechnology, FDA, Govt Agencies, Pharma / Biotech
FDA Grapples with Promise and Perils of Gene Therapy
Biotech startup AviadoBio emerges with $80M for neuro disorder gene therapies
Genetic diagnosis of rare diseases up with genome sequencing
How can scientists update coronavirus vaccines for omicron?
Most effective COVID-19 boosters are mRNA vaccines, study shows